Drug Trial Radar · NCT05338099
Determine the Safety and Dose of EN001 in Patients With Duchenne Muscular Dystrophy(DMD)
Last checked: Nov 20, 2026Latest source record: Aug 30, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
7
Actual
Start
Jan 18, 2022
Primary completion
Dec 28, 2022
Study completion Dec 28, 2022
Sponsor
- Lead sponsor
- ENCellIndustry
- Sponsor type
- Industry
- First posted
- Apr 20, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 2 years, up to 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Open-label, Dose-escalation, Phase 1 Clinical Trial to Determine the Safety and Dose of EN001 in Patients with Duchenne Muscular Dystrophy(DMD)
Conditions
- Duchenne Muscular Dystrophy
Interventions
EN001Drug
EN001 intravenously (IV) in the treatment of Duchenne Muscular Dystrophy (DMD) Dosage for each group is as follows. Dose group A (Low dose): 5.0x10\^5 cells/kg
EN001Drug
EN001 intravenously (IV) in the treatment of Duchenne Muscular Dystrophy (DMD) Dosage for each group is as follows. Dose group B (High dose): 2.5x10\^6 cells/kg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants of any Adverse Events (AEs)/Serious Adverse Events (SAEs) related investigational productTime frame: Week 12 after treatment
- Determination of Dose-limiting toxicity (DLT) levels of EN001Time frame: Up to Week 2 after dosing on Day 0
- Determination of Maximum tolerated dose (MTD) levels of EN001Time frame: Up to Week 2 after dosing on Day 0
- Number of participants with Vital Signs abnormalitiesTime frame: Week 12 after screening
- Number of participants with clinically significant abnormalities of Physical ExaminationsTime frame: From screening up to Week 12
- Number of participants with abnormalities of Laboratory ParametersTime frame: From screening up to Week 12
- Number of participants with abnormalities of 12-lead Electrocardiography (ECG)Time frame: From screening to baseline on Day 0 (Predose to end of infusion and 90 min after completion of infusion)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Samsung Medical Center
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.